StockData
Precision BioSciences Inc logo

Precision BioSciences Inc (DTIL) company profile

DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)

Close on Nov 17, 2026Market cap $194.59MP/E –Yield –

About Precision BioSciences

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a clinical-stage genome editing biotechnology company that develops in vivo gene editing therapies using its proprietary ARCUS platform. Its technology enables complex genetic modifications, such as inserting functional genes, eliminating viral genomes, and excising defective genetic sequences. The company's primary internal drug candidates include PBGENE-HBV, aimed at treating chronic hepatitis B by eliminating viral DNA, and PBGENE-DMD, designed to treat Duchenne muscular dystrophy through targeted gene excision. Additionally, the company collaborates with external pharmaceutical partners on programs such as ECUR-506 for ornithine transcarbamylase deficiency, and licenses its technology for therapeutic research and development. Its end customers and beneficiaries are patients suffering from severe genetic disorders and infectious diseases.

The organization conducts clinical trials across several regions, including the United States, New Zealand, Hong Kong, Moldova, Australia, and Spain. Its workforce includes nineteen full-time personnel holding doctoral or medical degrees. The provided text does not identify the location of the corporate headquarters.

Summary of the business section of Precision BioSciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Precision BioSciences Inc
Headquarters
Durham, NC
Address
302 East Pettigrew Street, Suite A-100 27701
Phone
(919) 314-5512
Employees
68, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
May 21
Auditor
Deloitte & Touche LLP, Raleigh, North Carolina

Stock & identifiers

Ticker
DTIL
Exchange
Nasdaq
IPO date
Mar 28, 2019
Shares outstanding
28M, Aug 3, 2026
Public float
$47.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Feb 14, 2024
SEC CIK
1357874
CUSIP
74019P207
ISIN
US74019P2074
FIGI
BBG008NSBPV3
Share class FIGI
BBG008NSBPW2
LEI
549300I5QGRS3BLHZH41
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael AmorosoPresident and CEO, Director243,392
Dario ScimecaChief Legal Officer56,782
Naresh Haresh TannaChief Financial Officer25,575
Cassandra Louise GorsuchChief Scientific Officer16,028
Mei Zhang Lu BurrisChielf Accounting Officer5,115
John Alexander KellyChief Financial Officer125,883
J. Jefferson SmithChief Research Officer129,857
Stanley FrankelDirector41,478
Geno J. GermanoDirector47,492
Melinda BrownDirector45,481
Kevin BuehlerDirector49,137
Shari Lisa PireDirector35,028

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.19M$2.26M$1.02M$12–
FY2024$4.31M$2.00M$1.67M$11–
FY2023$2.04M-$206.56K$997.18K$31–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Michael Amoroso
President, Chief Executive Officer and Director
$650.88K$451.29K$1.03M$62.21K$2.19M-49%
Alex Kelly
Chief Financial Officer
$472.53K$222.22K$417.06K$22.31K$1.13M-40%
Dario Scimeca
General Counsel and Secretary
$445.88K$193.56K$252.00K$20.21K$911.64K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 28, 2019
Offer price
$16.00
Securities offered
7,900,000
Gross proceeds
$126.40M
Exchange
Nasdaq
First trading day
Mar 28, 2019
First-day close
$17.44+9.0%
Lock-up ends (est.)
Sep 24, 2019

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 68 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?